The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
Hosted on MSN7h
Astrazeneca (AZN) Rises As Market Takes a Dip: Key FactsAstrazeneca (AZN) closed the latest trading day at $70.25, indicating a +0.95% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.47%. Meanwhile, the Dow ...
Dear reader, China’s biotechnology sector has rapidly emerged as one of the fastest-growing industries, with Chinese players ...
AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback